Clinical Trial

Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to use Claudin 18.2 (CLDN18.2)-targeted positron emission tomography (PET) imaging technology to evaluate its detection efficacy and diagnostic threshold for CLDN18.2-positive pancreatic cancer and gastric/gastroesophageal junction cancer, analyze the quantitative value of PET parameters in CLDN18.2 expression and their correlation with prognosis, and provide a basis for the precise selection of CLDN18.2-targeted therapy.
Trial Details
NCT Number NCT07554742
Lead Sponsor Ruijin Hospital
Conditions Pancreatic Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
Enrollment 64 participants
Start Date 2026-04-15
Primary Completion 2029-03-31 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-28